Introduction
============

*Enterococcus* is a catalase-negative, gram-positive coccus. It is one of the important members of normal flora of the gastrointestinal tract of most warm-blooded organisms, including human beings. However, it has been suggested that different strains of gram-positive cocci could be opportunistic pathogens causing various infectious diseases.[@b1-ahmt-9-177],[@b2-ahmt-9-177] The most common human infectious strains of *Enterococcus* are *Enterococcus faecalis* (85%--90%) and *Enterococcus faecium* (10.5%), and they cause cause urinary tract infections, endocarditis, intra-abdominal abscesses, wound infections, bacteremia, sepsis in babies, etc.[@b2-ahmt-9-177]--[@b4-ahmt-9-177] In addition, it has been proven that *Enterococcus* is the second leading cause of urinary tract and wound infections and the third leading cause of bacteremia in hospitals.[@b2-ahmt-9-177],[@b3-ahmt-9-177]

The main reasons for the stability and development of *Enterococcus* in a hospital environment are as follows: inherent resistance to a wide range of antibiotics used in the treatment of infections caused by gram-positive bacteria; the ability of these bacteria to acquire resistance genes to antibiotics through mutation or acquisition of external genetic materials (plasmids, transposons, and mobile genetic indicators); and resistance gene transfer by conjugation or other transmission methods.[@b3-ahmt-9-177]--[@b5-ahmt-9-177] In addition, the evidence suggests that regardless of its virulence factors the pathogenic strength of *Enterococcus* is because of inherent or acquired resistance to various antibiotics.[@b3-ahmt-9-177]

Antibiotics have been used to treat bacterial infections for almost 70 years.[@b6-ahmt-9-177]--[@b8-ahmt-9-177] Vancomycin with an antibiotic from the aminoglycoside family is prescribed instead of penicillin in the treatment of enterococcal infections. Due to the bactericidal activity of these antibiotics against *Staphylococcus* and other gram-positive bacteria which are resistant to methicillin, these drugs are widely used to treat and prevent against infections caused by these organisms.[@b4-ahmt-9-177] However, *Enterococcus* easily acquires antibiotic resistance and is able to transfer resistance genes to other strains.[@b5-ahmt-9-177] In most cases, vancomycin is prescribed as a last resort to treat infections of gram-positive bacteria, especially *Enterococcus*. However, in recent years, increased prescription of vancomycin in clinics plays a major role in vancomycin resistance of subjected pathogens.[@b9-ahmt-9-177] Because of its resistance against various antibiotics, vancomycin-resistant *Enterococcus* (VRE) has created a major problem in the treatment of patients.[@b3-ahmt-9-177]

It should be mentioned that antimicrobial resistance to antibiotics can be different worldwide depending upon genetic variations of subjected strains, differences in access to broad spectrum of antibiotics, etc.[@b10-ahmt-9-177] The acquisition of antibiotic resistance genes over time in different geographical areas and the resultant changed susceptibility pattern of bacteria to the antibiotics have led to an important issue. In this circumstance, the selection of an appropriate antibiotic for better treatment is a challenge.[@b11-ahmt-9-177],[@b12-ahmt-9-177] It is of high importance to determine the prevalence of antibiotic resistance to effectively treat and control enterococcal infections.[@b10-ahmt-9-177] Therefore, further studies with the aim of gaining knowledge about antibiotic resistance patterns are necessary to guide empirical and specific treatments against this pathogen.[@b13-ahmt-9-177],[@b14-ahmt-9-177]

One of the most important goals of meta-analyses is to provide an accurate and reliable result by increasing the sample size and reducing the width of the 95% CI from the range of the various applicable studies.[@b15-ahmt-9-177] So far, several studies in the field of antibiotic-resistant enterococci have been done. Since antibiotic treatment of infectious diseases caused by this organism is different based on epidemiology and antimicrobial resistance, it seems to be necessary to perform a meta-analysis study in this field to validate the results of studies and provide an accurate and reliable measure. This review was carried out to determine the prevalence of vancomycin resistance in *Enterococcus* isolates using a systematic literature review and meta-analysis method in Iran.

Materials and methods
=====================

Literature review
-----------------

A systematic review and meta-analysis was performed by searching Iranian databases including SID, Magiran, Iran-Doc, and IranMedex, and international databases MedLib, PubMed, ISI, Web of Science, Scopus, and Google Scholar to find published studies about the prevalence of resistance to vancomycin in *Enterococcus* isolates. The search was performed using Persian keywords and their English equivalent (clinical infections, gram-positive bacteria, enterococci, antibiotic resistance, glycopeptide antibiotics, vancomycin) with all possible combinations. In addition, the titles and references from selected articles were an additional search tool. To reduce the bias, the search process was conducted independently by two researchers.

Inclusion and exclusion criteria for studies
--------------------------------------------

We considered all cross-sectional or cohort studies that reported the prevalence of vancomycin resistance in *Enterococcus* isolates in patients suspected of having clinical infection. The published studies were examined in three steps: title, abstract, and full text. Exclusion criteria for the analysis were as follows: studies with insufficient information; studies that were not cross-sectional or cohort; studies that were done in other organisms except enterococci; review studies; abstracts of congresses; articles published in languages other than Persian and English; and systematic review, meta-analysis, and repetitive studies. In addition, to check the quality control of the data, the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE)[@b1-ahmt-9-177] checklist was used. This checklist has 22 parts that cover different sections of reports. In addition, each section was scored between 0 and 2, and the total score for each article was calculated.[@b16-ahmt-9-177] If necessary, the authors were contacted for further information.

Data extraction
---------------

After determining the quality of studies, the following data were extracted: first author; year of publication; year of study; place of study; sample size; sample type; prevalence of all kinds of *Enterococcus* and their resistance to vancomycin; prevalence of complete resistance, prevalence of mean resistance, and prevalence of sensitivity to vancomycin in *Enterococcus* isolates; and antimicrobial susceptibility determination methods and the criteria of antibiotic susceptibility test ([Table 1](#t1-ahmt-9-177){ref-type="table"}). Data extraction was carried out independently by two researchers, and if the results did not match, study investigators resolved the differences together. Afterward, the extracted data were entered into an Excel spreadsheet to perform statistical analyses.

Statistical analyses
--------------------

Since the main index of the review was the value of prevalence, its variance and 95% CI were calculated by considering the binomial distribution. To combine the prevalence values of various studies, the variance of the weighted mean was used to calculate the 95% CIs. Each study was given weight proportional to its inverse variance. The heterogeneity was investigated using the *Q*-test and *I*^2^ index at a significance level of \<10%. In addition, due to the heterogeneity of studies, the random-effects model was used in this meta-analysis. The results were plotted in forest plots (point estimates and 95% CI). Finally, to analyze the data, R and STATA (version 11.2; StataCorp LP, College Station, TX, USA) software were used.

Antibiotic resistance definition
--------------------------------

In most studies, the criteria of antibiotic sensitivity and resistance were as follows: minimum inhibitory concentra tion (MIC) \<8 mg/dL as sensitivity, MIC 8--16 mg/dL as intermediate, and MIC \>18 mg/dL was considered resistant. In some studies, MIC \>32 mg/dL was defined as complete resistance and MIC \>256 mg/dL or MIC \>500 mg/dL was defined as high-level resistance.

Results
=======

Fifty-three articles were found by searching Iranian databases including SID, Magiran, IranDoc, and IranMedex, and international databases MedLib, PubMed, ISI, Web of Science, Scopus, and Google Scholar. After primary evaluation, 12 articles were excluded from the study based on the titles and abstracts. In addition, another three articles were removed because of the unavailability of the full text. Therefore, 38 articles remained for studying the full text. In the next step, and after evaluating the full-text articles, 18 articles were excluded (three review articles, five duplicate articles, three low-quality articles, and seven articles due to insufficient information) and finally 20 articles published between 2000 and 2011[@b1-ahmt-9-177],[@b3-ahmt-9-177],[@b17-ahmt-9-177]--[@b34-ahmt-9-177] were entered into the meta-analysis ([Figure 1](#f1-ahmt-9-177){ref-type="fig"}). General information and data about these articles are summarized in [Table 1](#t1-ahmt-9-177){ref-type="table"}.

As mentioned previously, due to the heterogeneity of studies, the random-effects model was used in all next steps. According to this model, it is assumed that the observed differences derive from different samplings and differences in measured parameters (prevalence of enterococcal resistance in Iran) in studies.

In this review, a total of 6,829 *Enterococcus* isolates from inpatients and outpatients were analyzed. The samples were obtained from urine, stool, rectal swab, wound, blood, sterile liquid, lung secretion, abscess, catheter, etc. Although isolates were different based on sampling locations, most of the isolates were obtained from urine (\>70%).

In most studies, *Enterococcus*-type identification was performed through biochemical tests. As summarized in [Table 2](#t2-ahmt-9-177){ref-type="table"}, *E. faecalis* and *E. faecium* are the most common *Enterococcus* strains that cause clinical infections with a frequency of 69% (95% CI: 74, 64) and 28% (95% CI: 24, 32), respectively. In addition, the frequency of other types of *Enterococcus* is \~3% (95% CI: 1, 4).

[Figure 2](#f2-ahmt-9-177){ref-type="fig"} shows the frequency of full-resistant, intermediate-resistant, and sensitive isolates of *Enterococcus* to vancomycin. *Enterococcus* isolates were sensitive to vancomycin antibiotic at a rate of 74% (95% CI: 65, 83). The frequency of intermediate- and full-resistant isolates to vancomycin at rates of 14% (95% CI: 5, 23) and 14% (95% CI: 11, 18), respectively. [Figure 3](#f3-ahmt-9-177){ref-type="fig"} shows the prevalence of resistance to vancomycin in *Enterococcus* isolates in Iran and 95% CI in the reviewed studies.

In addition, the prevalence of vancomycin resistance among isolates of *E. faecalis* and *E. faecium* was 3% (95% CI: 2, 5) and 33% (95% CI: 21, 45), respectively. These findings show that vancomycin resistance among *E. faecium* isolates is significantly higher than that among *E. faecalis* isolates ([Table 2](#t2-ahmt-9-177){ref-type="table"}).

In this review, the amount of resistance was also evaluated based on sample type. As mentioned earlier, \>70% of isolates were obtained from urine samples. The remaining \<30% of isolates were mostly extracted from stool samples, and other few isolates were extracted from different clinical samples. Therefore, the analysis in subgroups of the samples was limited to only three groups: urine, stool, and other clinical samples. Accordingly, vancomycin resistance in *Enterococcus* isolates obtained from urine samples was 15% (95% CI: 10, 19), stool samples was 16% (95% CI: 9, 23) and other samples was 12% (95% CI: 10, 14; [Table 3](#t3-ahmt-9-177){ref-type="table"}). The results do not show significant differences in this area ([Figure 4](#f4-ahmt-9-177){ref-type="fig"}).

Another result of this review was to study the prevalence of vancomycin resistance among isolates of *Enterococcus* based on patients' status (inpatients, outpatients). The results showed that vancomycin resistance among *Enterococcus* isolates obtained from inpatients was significantly higher than that from outpatients (16% vs 1%; [Table 3](#t3-ahmt-9-177){ref-type="table"}). Based on the results of this review, genotype van A had the highest frequency of resistance to vancomycin ([Table 2](#t2-ahmt-9-177){ref-type="table"}). In addition, we found that among total strains with resistance to vancomycin, 86% (95% CI: 73, 98) were genotype van A and 20% (95% CI: 16, 24) were genotype van B.

Discussion
==========

*Enterococcus* is the second leading cause of urinary tract infections and the third leading cause of bacteremia. In addition, in the past two decades, *Enterococcus* was introduced as the third leading cause of hospital-acquired infections after *Escherichia coli* and *Staphylococcus*.[@b35-ahmt-9-177] It has been evidenced that *Enterococcus* is responsible for 10%--20% of all hospital infections, 10%--12% urinary tract infections in hospitals, and 5%--10% of hospital bacteremia.[@b36-ahmt-9-177] Diagnosis and treatment of clinical infections are vital, and a delay in treatment may result in irreversible harm to patients. Because of improper antibiotic consumption due to self-medication in our society, urine and stool cultures of patients were often reported as negative. Therefore, in many cases, the treatment was based on the most common urinary infection strains and their antibiotic susceptibility.[@b37-ahmt-9-177] In this review, we aimed to determine the prevalence of vancomycin resistance among the most common cause of clinical infections (*Enterococcus*) in Iran by using systematic reviews and meta-analyses.

The results of this review indicate that two species, namely *E. faecalis* and *E. faecium*, are the most common *Enterococcus* strains that cause human infections. We found that 69% of the isolated species belong to *E. faecalis* and 28% belong to *E. faecium*. In addition, we observed that this distribution is different among various geographical places; in several studies in countries such as Iran, USA, UK, and many European countries, *E. faecalis* is the dominant isolated species. However, a few reports showed that in some countries, such as India and Japan, *E. faecium* formed a higher percentage of *Enterococcus*.[@b38-ahmt-9-177] In Yeh et al's study, \>90% of *Enterococcus* isolates were *E. faecalis* and the remaining 10% were *E. faecium*.[@b39-ahmt-9-177] Enterococcus faecalis has a higher role in enterococcal infections due to high connectivity and proliferation in the intestine. But, high potential of *E. faecium* in the acquisition of resistance materials (genes, mutations, plasmids, etc.) makes this strain highly resistant to various antibiotics.[@b40-ahmt-9-177],[@b41-ahmt-9-177] As the results of this review showed that the prevalence of *E. faecalis* was higher than that of *E. faecium* (69% vs 28%), the prevalence of resistance to vancomycin among *E. faecium* isolates was considerably higher than that of *E. faecalis* isolates (33% vs 3%). In addition, the prevalence of vancomycin-resistant genes among *E. faecium* isolates was higher than that of *E. faecalis* (85% vs15%). Many studies showed that *E. faecium* has high resistance, and it is the dominant species among VRE.[@b19-ahmt-9-177],[@b42-ahmt-9-177] This property is indicative of the important role of *E. faecium* in the spread of resistance to vancomycin.

The results of this review showed that 16% of colonized *Enterococcus* isolates in inpatients were resistant to vancomycin. In addition, the amount of vancomycin resistance in *Enterococcus* isolates obtained from inpatients was significantly higher than that from outpatients (16% vs 1%). A study in France reported that the frequency of resistance to vancomycin was 37% for inpatients and 11.8% for outpatients.[@b43-ahmt-9-177] VRE is of high risk for inpatients. A study in the USA showed that the percentage of *Enterococcus* isolates resistant to vancomycin in hospital ICUs is on the rise.[@b44-ahmt-9-177] VRE is an important factor in hospital-acquired infections and can lead to increased rate of diseases, mortality, and costs.[@b45-ahmt-9-177]--[@b47-ahmt-9-177] It is possible that excessive consumption of vancomycin and other antibiotics, such as cephalosporins, plays a key role in the colonization of VRE.[@b47-ahmt-9-177],[@b48-ahmt-9-177] Benenson et al's[@b49-ahmt-9-177] study of 1,215 inpatients showed that 9.8% of patients were fecal carriers of VRE and previous hospitalization and antibiotic treatment are important risk factors. The results of Cohen et al's[@b50-ahmt-9-177] study of 1,039 patients in different phases showed that VRE carriers are 3.8% of patients at reception, 15% of discharged patients, and 32% in inpatients.

In this review, the rate of vancomycin resistance in *Enterococcus* isolates based on the place of the sampling did not show a significant difference. In addition, most samples were obtained from urine (\>70%) and this shows the importance of *Enterococcus* colonization in the urinary tract after hospitalization of patients. Different studies have shown that *Enterococcus* is the leading cause of urinary tract infection among gram-positive cocci and the third leading cause of bacterial infection in women's urinary tracts in Iran after *E. coli* and *Klebsiella pneumonia*.[@b19-ahmt-9-177]

The results of this review showed that vancomycin resistance in *Enterococcus* isolates in Iran is 14%. The prevalence of vancomycin resistance in South Korea, Belgium, and England was reported as 16%,[@b51-ahmt-9-177] 12.8%,[@b52-ahmt-9-177] and 12.2%,[@b53-ahmt-9-177] respectively. These results are close to our results in this subject. Some studies have reported a lower prevalence, eg, in Spain only three cases were resistant to vancomycin from 437 Enterococcus samples.[@b54-ahmt-9-177] A prevalence of 6.7% was reported in a study in Canada,[@b55-ahmt-9-177] 9% in a study in New York,[@b56-ahmt-9-177] and 2%--9% in a separate study in the USA.[@b57-ahmt-9-177]--[@b60-ahmt-9-177] In soEurope, a prevalence of 1% in France and 59% in Portugal was reported.[@b61-ahmt-9-177] This may be a reflection of drug and antibiotic utilization patterns in a region.

Drug resistance to antibiotics is different due to genetic changes in strains, difference in antibiotic utilization, and differences in access to broad-spectrum and new antibiotics in different regions of Iran and the world. Some predisposing factors should be considered in *Enterococcus* colonization or infection with these microorganisms in patients. These factors can be listed as a long stay in hospital, inappropriate use of third-generation antibiotics, such as cephalosporins and vancomycin, organ transplants, taking metronidazole, surgery, diabetes, leukemia, weakened immune system for any reason, and kidney failure.[@b23-ahmt-9-177]

Based on our findings, van A has a higher frequency of resistance to vancomycin. From all vancomycin-resistant strains, 80% had genotype van A and 20% had genotype van B. The most important vancomycin-resistant genes are van A, van B, van C1, and van C2/C3. Van A and B (as the most important genes for resistance) are on transposons, such as Tn1546 and Tn1547, respectively, and they can be found in plasmids or chromosomes.[@b1-ahmt-9-177] Increased resistance to glyco-peptides, such as vancomycin, results in limited therapeutic and drug choices because an alternative treatment in Iran has not improved. In addition, it increases the risk of transferring resistance genes to other bacteria, such as *Staphylococcus*.[@b1-ahmt-9-177]--[@b3-ahmt-9-177] On the other hand, the infections caused by *Enterococcus* that are resistant to several antibiotics are also increasing simultaneously. Vancomycin is the optional drug for infections caused by multi-resistance strains. Reports showed that multidrug resistance is usually observed in patients who have been recently treated with antibiotics. Resistant strains, especially multidrug resistant strains are colonized in these patients' gastrointestinal tracts because the sensitive strains have been eliminated with antibiotic treating. In this way, the direct and indirect transfer rates of resistant strains increase.[@b31-ahmt-9-177] Multidrug-resistant *Enterococcus* strains are causing a series of problems, including the emergence of resistance to ami-noglycosides and beta-lactams. If resistance to vancomycin is found, the situation will become more critical. Therefore, using newer compounds, such as oxazolidinedione and streptogramin, in the treatment of patients can somewhat reduce this problem.[@b19-ahmt-9-177]

One of the main limitations of this review was in the checking of the prevalence of resistance to vancomycin separately for males and females because the resistance was calculated separately for the two sexes in only a very small number of studies. Patients' age is an important factor which may contribute in antibiotic resistance. Since in most studies the details of age were not mentioned and because of nonexistent studies of similar age groups, we could not calculate resistance values according to age. Another limitation in our review was the lack of unit definition of resistance in the analysis of the literature that was used. In addition, the lack of access to the full text of some articles was another limitation of this review.

Conclusion
==========

Drug-resistant *Enterococcus* is an important epidemic cause of nosocomial infections and can increase disease, mortality, and costs. Vancomycin is an antibiotic that because of its activity against methicillin-resistant *Staphylococcus aureus* and other gram-positive bacteria can be used widely for the treatment and prevention of infections caused by these organisms. According to the results, there was a high resistance to this drug in *Enterococcus* strains in many regions of Iran, whereas in many developed countries there is a low resistance. Therefore, there is a difference in the pattern of bacterial sensitivity and resistance in different geographic regions. In addition, the use of methods that are able to detect resistant strains and application of them in prevention strategy design to control the spread of resistant strains is important. To limit the drug-resistant *Enterococcus* prevalence, it is necessary to be cautious in using vancomycin. Also, permanent control of the prevalence of glycopeptide-resistant *Enterococcus* strains is essential in a hospital environment.
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![Frequency of resistance and sensitivity to vancomycin in *Enterococcus* isolates.\
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![The prevalence of vancomycin resistance in *Enterococcus* isolates in Iran and its 95% CI in the reviewed studies based on the author's name and year of study.\
**Notes:** Each squares shows the estimation prevalence of each study. The diamond symbol shows the prevalence values in Iran in all studies. Weights are from random-effects analysis.\
**Abbreviation:** ES, effect size.](ahmt-9-177Fig3){#f3-ahmt-9-177}

![The prevalence of vancomycin resistance in *Enterococcus* isolates in Iran and its 95% CI according to sample type: 1) urine, 2) stool, and 3) other clinical samples.\
**Note:** Weights are from random-effects analysis.\
**Abbreviation:** ES, effect size.](ahmt-9-177Fig4){#f4-ahmt-9-177}

###### 

Obtained results of selected studies in the meta-analysis of prevalence of vancomycin resistance among *Enterococcus* isolates in Iran

  Study                                    City                  Sample size   The prevalence of *Enterococcus* (%)   The prevalence of resistance to vancomycin (%)   The prevalence of resistance in *Enterococcus* (%)   The prevalence of van A and van B in resistant strains   Sample type            Antibiotic susceptibility test and determination of MIC                                                                                                                                                                                            
  ---------------------------------------- --------------------- ------------- -------------------------------------- ------------------------------------------------ ---------------------------------------------------- -------------------------------------------------------- ---------------------- --------------------------------------------------------- ------- --------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------
  Mohammadi et al[@b1-ahmt-9-177]          Kermanshah and Ilam   180           71                                     29                                               MICs ≥256 µg/mL: 8.3                                 29                                                                                                                                        --      15 resistant strains 12→vanA 3→van B                                              Urine, wound, blood, sterile body fluid, lung secretion, abscess, catheter                     Disk diffusion method according to CLSI and E-test
  Dadfarma et al[@b3-ahmt-9-177]           Tehran                142           63                                     33                                               7.74                                                 33                                                                              0                                                         23.4                                                                                      Urine, blood culture, wound, endotracheal tube, pleural fluid                                  Broth microdilution and disk diffusion methods
  Ghasemi et al[@b17-ahmt-9-177]           Kashan                106           100                                    0                                                MICs ≥32 µg/mL: 4.7                                  0                                                        MICs ≤4 µg/mL: 89.6    4.7                                                                                                                                                 Stool or rectal swab                                                                           Disk diffusion method according to CLSI
  Vahhabi et al[@b18-ahmt-9-177]           Tabriz                291           64.9                                   29.5                                             MICs ≥32 µg/mL: 5.1                                  29.5                                                     MICs \<8 µg/mL: 78.4   0                                                         17.44   15 resistant strains (*E. faecium*) 12 →van A 3→van B                             Urine, blood, wound, other organ                                                               Agar dilution or E-test method
  Feizabadi et al[@b19-ahmt-9-177]         Tehran                339           77.5                                   22.5                                             MICs ≥2,000 µg/mL: 2.06                              22.5                                                                            0                                                         11      7 resistant strains (*E. faecium*) all containing van A                           Urine, blood, wound, body fluid, intravenous catheter                                          Kirby--Bauer or dilution method
  Sharifi et al[@b20-ahmt-9-177]           Tabriz and Orumieh    220           69.1                                   30.9                                             MICs ≥256 µg/mL: 20.5                                30.9                                                                            6.57                                                      51.47   45 resistant strains 43→van A (8 *E. faecalis*, 35 *E. faecium*) van B→0          Urine, blood, wound, body fluid, intravenous catheter, bile, sputum, endotracheal tube, boil   Disk diffusion and agar dilution methods
  Shokoohizadeh et al[@b21-ahmt-9-177]     Tehran                222           51.3                                   41.4                                             MICs ≥128 µg/mL: 48.9                                41.4                                                                                                                                      48.9                                                                                      Stool                                                                                          
  Ghaffarpasand et al[@b22-ahmt-9-177]     Kashan                100                                                  27                                               MICs ≥32 µg/mL: 34                                   27                                                       MICs ≤4 µg/mL: 56                                                                                                                                                          Urine, wound, blood, sputum                                                                    Kirby--Bauer disk diffusion method
  Hosseinizadeh et al[@b23-ahmt-9-177]     Arak                  150                                                                                                   MICs ≥32 µg/mL: 14.6                                                                                          MICs ≤4 µg/mL: 55.4                                                                                                                                                        Rectal swab                                                                                    Broth microdilution method
  Askarian et al[@b24-ahmt-9-177]          Shiraz                700                                                                                                   14.1                                                                                                          8.42                                                                                                                                                                       Rectal swab                                                                                    
  Fatholahzadeh et al[@b26-ahmt-9-177]     Tehran                120           57                                     30                                               MICs ≥512 µg/mL: 7                                   30                                                                              0                                                         5.55    15 resistant strains all containing van A                                         Urine                                                                                          Agar disk diffusion method according to the NCCLS guide and agar dilution method
  Haghi-Ashteiani et al[@b27-ahmt-9-177]   Tehran                100                                                                                                   46                                                                                                                                   4.7                                                                                                                                                 Urine                                                                                          Disk diffusion test
  Feizabadi et al[@b28-ahmt-9-177]         Tehran                103           83.5                                   16.5                                             MICs ≥256 µg/mL: 11.65                               16.5                                                                            0                                                         71.4                                                                                      Stool                                                                                          Disk diffusion test
  Javadi et al[@b29-ahmt-9-177]            Isfahan               58                                                                                                    MICs ≥256 µg/mL: 29.3                                                                                         MICs ≤4 µg/mL: 46.6    0                                                                                                                                                                                                                                                  E-test
  Aligholi et al[@b30-ahmt-9-177]          Tehran                495           67                                     32                                               MICs ≥64 µg/mL: 11                                   32                                                       MICs ≤4 µg/mL: 88.5    6.57                                                              55 resistant strains 44 → van A                                                   Urine                                                                                          Agar dilution method according to CLSI guidelines
  Saifi et al[@b31-ahmt-9-177]             Tehran                638           77.8                                   22.2                                             16.93                                                22.2                                                                            --                                                                                                                                                  Urine, wound, blood, body fluid, respiratory tract, and abscess                                Disk diffusion and microdilution method
  Pourshafie et al[@b32-ahmt-9-177]        Tehran                900                                                                                                   MICs ≥128 µg/mL: 5.4                                                                                                                                                                                   49 resistant strains all containing van A                                         Urine                                                                                          NCCLS guidelines
  Rahbar et al[@b33-ahmt-9-177]            Tehran                837           79.8                                   20.2                                             7.76                                                 20.2                                                     91.75                                                                                                                                                                      Urine                                                                                          Disk diffusion method according to CLSI guidelines
  Emaneini et al[@b34-ahmt-9-177]          Tehran                326           64.3                                   35.7                                             MICs ≥32 µg/mL: 12                                   35.7                                                     4                                                                                        38 resistant strains (30 *E. faecium* and 8 *E. faecalis*) all containing van A   Urine, blood, wound, and other clinical sample                                                 Disk diffusion method according to CLSI

**Abbreviations:** CLSI, Clinical & Laboratory Standards Institute; *E. faecalis*, *Enterococcus faecalis*; *E. faecium*, *Enterococcus faecium*; MIC, minimum inhibitory concentration; NCCLS, National Committee for Clinical Laboratory Standards..

###### 

Results of the selected meta-analysis studies on the prevalence of vancomycin resistance among *Enterococcus* isolates in Iran

  Types of *Enterococcus*   Prevalence value (%) (95% CI)   VRE (%) (95% CI)   Prevalence value of van A (%) (95% CI)   Prevalence value of van B (%) (95% CI)
  ------------------------- ------------------------------- ------------------ ---------------------------------------- ----------------------------------------
  *E. faecalis*             69 (64--74)                     3 (2--5)           15 (0--30)                               NR
  *E. faecium*              28 (24--32)                     33 (21--45)        85 (70--100)                             NR
  Other *Enterococcus*      3 (1--4)                        NR                 NR                                       NR
  Total                     100                             14 (11--18)        80 (70--90)                              20 (16--24)

**Abbreviations:** E. faecalis, Enterococcus faecalis; E. faecium, Enterococcus faecium; NR, not reported; VRE, vancomycin-resistant Enterococcus.

###### 

The prevalence of vancomycin resistance among *Enterococcus* isolates according to patients' status

  Variables                                                    Number of studies   Vancomycin resistance value (%) (95% CI)
  ------------------------------------------------ ----------- ------------------- ------------------------------------------
  Resistance value according to sample type        Urine       12                  15 (10--19)
  Stool                                            5           16 (9--23)          
  Other samples                                    3           12 (10--14)         
  Resistance value according to patients' status   Inpatient   11                  16 (11--22)
  Outpatient                                       3           1 (0--2)            
